{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:27:43Z","timestamp":1769113663461,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2022M723207"],"award-info":[{"award-number":["2022M723207"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014759","name":"Medical Scientific Research Foundation of Zhejiang Province of China","doi-asserted-by":"crossref","award":["2023KY666"],"award-info":[{"award-number":["2023KY666"]}],"id":[{"id":"10.13039\/501100014759","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Zhejiang Traditional Chinese Medicine Science Fund Project","award":["2024ZL372"],"award-info":[{"award-number":["2024ZL372"]}]},{"name":"Qiantang Cross Fund Project","award":["2023-16"],"award-info":[{"award-number":["2023-16"]}]},{"name":"Medical Scientific Research Foundation of Zhejiang Province","award":["2022KY639"],"award-info":[{"award-number":["2022KY639"]}]},{"name":"Medical Scientific Research Foundation of Zhejiang Province","award":["2022KY653"],"award-info":[{"award-number":["2022KY653"]}]},{"DOI":"10.13039\/501100013115","name":"Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013115","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11096-025-01917-z","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T03:27:15Z","timestamp":1745638035000},"page":"1305-1314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Post-marketing safety of pralsetinib: a real-world disproportionality analysis based on the FDA adverse event reporting system database"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8282-3913","authenticated-orcid":false,"given":"Zheng","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keda","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manyi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiayao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengbo","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"issue":"11","key":"1917_CR1","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1200\/JCO.19.02551","volume":"38","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, Yang D, Velcheti V, et al. State-of-the-art strategies for targeting RET-dependent cancers. J Clin Oncol. 2020;38(11):1209\u201321.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1917_CR2","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","volume":"23","author":"S Kato","year":"2017","unstructured":"Kato S, Subbiah V, Marchlik E, et al. RET aberrations in diverse cancers: next-generation sequencing of 4871 patients. Clin Cancer Res. 2017;23(8):1988\u201397.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1917_CR3","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1210\/en.2006-0921","volume":"148","author":"R Ciampi","year":"2007","unstructured":"Ciampi R, Nikiforov YE. RET\/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology. 2007;148(3):936\u201341.","journal-title":"Endocrinology"},{"issue":"3","key":"1917_CR4","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nm.2658","volume":"18","author":"K Takeuchi","year":"2012","unstructured":"Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378\u201381.","journal-title":"Nat Med"},{"issue":"3","key":"1917_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nm.2644","volume":"18","author":"T Kohno","year":"2012","unstructured":"Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012;18(3):375\u20137.","journal-title":"Nat Med"},{"issue":"3","key":"1917_CR6","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nm.2673","volume":"18","author":"D Lipson","year":"2012","unstructured":"Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18(3):382\u20134.","journal-title":"Nat Med"},{"issue":"7","key":"1917_CR7","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","volume":"8","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Gainor JF, Rahal R, et al. Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov. 2018;8(7):836\u201349.","journal-title":"Cancer Discov"},{"key":"1917_CR8","unstructured":"U.S. Food and Drug Administration, Drugs@FDA [database on the internet], GAVRETO. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/213721s015lbl.pdf. Accessed 31 Jan 2025."},{"key":"1917_CR9","unstructured":"U.S. Food and Drug Administration, Drugs@FDA [database on the internet], GAVRETO. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213721s000lbl.pdf. Accessed 31 Jan 2025."},{"issue":"7","key":"1917_CR10","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","volume":"22","author":"JF Gainor","year":"2021","unstructured":"Gainor JF, Curigliano G, Kim DW, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study. Lancet Oncol. 2021;22(7):959\u201369.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1917_CR11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","volume":"9","author":"V Subbiah","year":"2021","unstructured":"Subbiah V, Hu MI, Wirth LJ, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study. Lancet Diabetes Endocrinol. 2021;9(8):491\u2013501.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"1917_CR12","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","volume":"28","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Cassier PA, Siena S, et al. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial. Nat Med. 2022;28(8):1640\u20135.","journal-title":"Nat Med"},{"key":"1917_CR13","unstructured":"European Medicines Agency, Medicines, Gavreto. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/gavreto-epar-product-information_en.pdf. Accessed 31 Jan 2025."},{"key":"1917_CR14","unstructured":"The China National Medical Products Administration has granted conditional approval for the marketing of Pralsetinib capsules. https:\/\/www.nmpa.gov.cn\/zhuanti\/ypqxgg\/gggzjzh\/20210324140443175.html. Accessed 31 Jan 2025."},{"key":"1917_CR15","doi-asserted-by":"crossref","unstructured":"Lin C, Wang S, Xie W, et al. The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis. Cancer Biol Ther. 2015;16(7):1019\u201328.","DOI":"10.1080\/15384047.2015.1046649"},{"issue":"12","key":"1917_CR16","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1016\/j.jtho.2020.08.011","volume":"15","author":"AC Tan","year":"2020","unstructured":"Tan AC, Seet AOL, Lai GGY, et al. Molecular characterization and clinical outcomes in RET-rearranged NSCLC. J Thorac Oncol. 2020;15(12):1928\u201334.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"1917_CR17","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jtho.2022.12.018","volume":"18","author":"M Aldea","year":"2023","unstructured":"Aldea M, Marinello A, Duruisseaux M, et al. RET-MAP: an international multicenter study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion. J Thorac Oncol. 2023;18(5):576\u201386.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"1917_CR18","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.annonc.2022.08.002","volume":"33","author":"F Griesinger","year":"2022","unstructured":"Griesinger F, Curigliano G, Thomas M, et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol. 2022;33(11):1168\u201378.","journal-title":"Ann Oncol"},{"issue":"5","key":"1917_CR19","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1210\/endrev\/bnad013","volume":"44","author":"ML Gild","year":"2023","unstructured":"Gild ML, Clifton-Bligh RJ, Wirth LJ, et al. Medullary thyroid cancer: updates and challenges. Endocr Rev. 2023;44(5):934\u201346.","journal-title":"Endocr Rev"},{"issue":"1","key":"1917_CR20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1021\/acs.chemrestox.9b00387","volume":"33","author":"SD Lamore","year":"2020","unstructured":"Lamore SD, Kohnken RA, Peters MF, et al. Cardiovascular toxicity induced by kinase inhibitors: mechanisms and preclinical approaches. Chem Res Toxicol. 2020;33(1):125\u201336.","journal-title":"Chem Res Toxicol"},{"issue":"6","key":"1917_CR21","first-page":"e15441","volume":"13","author":"A Papaila","year":"2021","unstructured":"Papaila A, Jacobson AT. Into the unknown: a case of new-onset cardiomyopathy in a patient treated with recently approved tyrosine kinase inhibitor, pralsetinib. Cureus. 2021;13(6):e15441.","journal-title":"Cureus"},{"key":"1917_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17460441.2023.2279669","volume":"19","author":"Y Hou","year":"2024","unstructured":"Hou Y, Ren X, Chen Y, et al. Cardiovascular toxicities of selective ret-specific tyrosine kinase inhibitors: a pharmacovigilance study based on the United States food and drug administration adverse event reporting system database. Expert Opin Drug Saf. 2024;19:1\u20139.","journal-title":"Expert Opin Drug Saf"},{"key":"1917_CR23","doi-asserted-by":"publisher","first-page":"1024365","DOI":"10.3389\/fonc.2022.1024365","volume":"12","author":"L An","year":"2022","unstructured":"An L, Chen P, Wang J, et al. Case report: recurrent lung infections following treatment with pralsetinib for an elderly patient with RET-fusion positive NSCLC. Front Oncol. 2022;12:1024365.","journal-title":"Front Oncol"},{"key":"1917_CR24","first-page":"107815522413040","volume":"18","author":"A Lehman","year":"2024","unstructured":"Lehman A, Perissinotti A, Aitken S. Cytomegalovirus viremia and hepatitis B reactivation in patient with RET fusion-positive non-small cell lung cancer treated with pralsetinib. J Oncol Pharm Pract. 2024;18:10781552241304000.","journal-title":"J Oncol Pharm Pract"},{"key":"1917_CR25","doi-asserted-by":"publisher","first-page":"1402902","DOI":"10.3389\/fmed.2024.1402902","volume":"11","author":"F Poumeaud","year":"2024","unstructured":"Poumeaud F, Jaffrelot M, Gomez-Roca C, et al. A double-edged sword: unusual multiple severe infections with pralsetinib: a case report and literature review. Front Med. 2024;11:1402902.","journal-title":"Front Med"},{"key":"1917_CR26","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ejca.2021.09.037","volume":"159","author":"YP Lee","year":"2021","unstructured":"Lee YP, Jeong BH, Eun Y, et al. Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: a Korean single-centre compassionate use experience. Eur J Cancer. 2021;159:167\u201373.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1917_CR27","doi-asserted-by":"publisher","first-page":"e494","DOI":"10.1097\/MJT.0000000000001695","volume":"31","author":"Y Xie","year":"2024","unstructured":"Xie Y, Chen C, Huang JA. Hepatitis B virus reactivation after pralsetinib-targeted therapy in a patient with non-small cell lung cancer. Am J Ther. 2024;31(4):e494\u20137.","journal-title":"Am J Ther"},{"key":"1917_CR28","first-page":"9545243","volume":"2020","author":"R Dhital","year":"2020","unstructured":"Dhital R, Paudel A, Bohra N, et al. Herbaspirillum infection in humans: a case report and review of literature. Case Rep Infect Dis. 2020;2020:9545243.","journal-title":"Case Rep Infect Dis"},{"issue":"12","key":"1917_CR29","first-page":"671","volume":"31","author":"M Gao","year":"2023","unstructured":"Gao M, Zhang X, Yan H, et al. Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer. Support Care Cancer. 2023;31(12):671.","journal-title":"Support Care Cancer"},{"issue":"1","key":"1917_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.kint.2021.09.026","volume":"101","author":"C Ott","year":"2022","unstructured":"Ott C, Schmieder RE. Diagnosis and treatment of arterial hypertension 2021. Kidney Int. 2022;101(1):36\u201346.","journal-title":"Kidney Int"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01917-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-01917-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01917-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T08:31:27Z","timestamp":1757665887000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-01917-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1917"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-01917-z","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"21 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}